Methods for promoting wound healing and hair growth
US-2024181008-A1 · Jun 6, 2024 · US
Treatment of neuropathic corneal pain with ngf
US2024197829A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2024197829-A1 |
| Application number | US-202218554511-A |
| Country | US |
| Kind code | A1 |
| Filing date | Apr 13, 2022 |
| Priority date | Apr 13, 2021 |
| Publication date | Jun 20, 2024 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to methods of treating neuropathic corneal pain (NCP) comprising administration of nerve growth factor (NGF).
First claim
Opening claim text (preview).
1 - 10 . (canceled) 11 . A method of treating neuropathic corneal pain (NCP) in a subject in need thereof, comprising administration of a composition comprising NGF. 12 . The method according to claim 11 , wherein the NGF is rhNGF. 13 . The method according to claim 11 , wherein the subject is a patient suffering from NCP who responds to treatment with a topical anesthetic and/or who has mild inflammation. 14 . The method according to claim 13 , wherein the topical anesthetic is proparacaine. 15 . The method according to claim 11 , wherein the subject has a Dendritiform Cell Density (cells/mm 2 ) lower than 75. 16 . The method according to claim 15 , wherein the subject has a Dendritiform Cell Density (cells/mm 2 ) lower than 70. 17 . The method according to claim 11 , wherein the subject is a patient suffering from peripheral or mixed NCP. 18 . The method according to claim 11 , wherein the subject is a patient who does not suffer from dry eye disease (DED) and/or from neurotrophic keratitis (NK). 19 . The method according to claim 11 , wherein NGF is administered topically to an ocular surface of the subject, in the form of a pharmaceutical composition for ophthalmic use. 20 . The method according to claim 19 , wherein NGF is present in the pharmaceutical composition at concentrations ranging from about 0.0001% to about 0.5% w/v. 21 . The method according to claim 20 , wherein NGF is present in the pharmaceutical composition at concentrations ranging from about 0.001% to about 0.1% w/v. 22 . The method according to claim 21 , wherein NGF is present in the pharmaceutical composition at a concentration of about 0.002% w/v. 23 . The method according to claim 11 , wherein the NGF is administered between 3 and 6 times a day for a period between 4 and 12 weeks.
Assignees
Inventors
Classifications
for peripheral neuropathies · CPC title
Centrally acting analgesics, e.g. opioids · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Ophthalmic agents · CPC title
- A61K38/185Primary
Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2024197829A1 cover?
- The present invention relates to methods of treating neuropathic corneal pain (NCP) comprising administration of nerve growth factor (NGF).
- Who is the assignee on this patent?
- Dompe Farm Spa, Tufts Medical Ct Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K38/185. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Jun 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).